Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Edgewise Therapeutics
< Previous
1
2
Next >
Edgewise Therapeutics Announces Positive Topline Results from the CANYON Phase 2 Trial of Sevasemten in Individuals with Becker Muscular Dystrophy (Becker)
December 16, 2024
From
Edgewise Therapeutics
Via
Business Wire
Tickers
EWTX
Edgewise Provides Statement Regarding Company’s Relationship with Dr. Han Phan at Rare Disease Research
December 05, 2024
From
Edgewise Therapeutics
Via
Business Wire
Tickers
EWTX
Edgewise Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference on December 3, 2024
November 26, 2024
From
Edgewise Therapeutics
Via
Business Wire
Tickers
EWTX
Edgewise Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
November 07, 2024
From
Edgewise Therapeutics
Via
Business Wire
Tickers
EWTX
Edgewise Therapeutics to Present on Sevasemten (EDG-5506) for Becker Muscular Dystrophy (Becker) at the 29th International Annual Congress of the World Muscle Society
October 01, 2024
From
Edgewise Therapeutics
Via
Business Wire
Tickers
EWTX
Edgewise Therapeutics Announces Positive Top-Line Data from Phase 1 Trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM)
September 19, 2024
From
Edgewise Therapeutics
Via
Business Wire
Tickers
EWTX
Edgewise Therapeutics to Host Webcast Event to Discuss Top-Line Data from Phase 1 trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM) on Thursday, September 19 at 8:30 am Eastern Time
September 17, 2024
From
Edgewise Therapeutics
Via
Business Wire
Tickers
EWTX
Edgewise Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
August 08, 2024
From
Edgewise Therapeutics
Via
Business Wire
Tickers
EWTX
Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 15, 2024
May 10, 2024
From
Edgewise Therapeutics
Via
Business Wire
Tickers
EWTX
Edgewise Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
May 09, 2024
From
Edgewise Therapeutics
Via
Business Wire
Tickers
EWTX
Edgewise Therapeutics Appoints Arlene Morris to its Board of Directors
May 07, 2024
From
Edgewise Therapeutics
Via
Business Wire
Tickers
EWTX
Edgewise Therapeutics Doses First Patient in Phase 2 CIRRUS-HCM Trial of EDG-7500 in Obstructive Hypertrophic Cardiomyopathy (HCM)
May 06, 2024
From
Edgewise Therapeutics
Via
Business Wire
Tickers
EWTX
Edgewise Receives European Medicines Agency (EMA) Orphan Drug Designations for Sevasemten (EDG-5506) for the Treatment of Becker and Duchenne Muscular Dystrophies
April 23, 2024
From
Edgewise Therapeutics
Via
Business Wire
Tickers
EWTX
Edgewise Therapeutics Announces Positive Two-Year Topline Results from the ARCH Open Label Trial of Sevasemten (EDG-5506) in Adults with Becker Muscular Dystrophy (Becker)
April 15, 2024
From
Edgewise Therapeutics
Via
Business Wire
Tickers
EWTX
Edgewise Therapeutics Announces Upcoming Podium Presentation at the American College of Cardiology's 2024 Annual Scientific Session
March 28, 2024
From
Edgewise Therapeutics
Via
Business Wire
Tickers
EWTX
Edgewise Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium on April 2, 2024
March 27, 2024
From
Edgewise Therapeutics
Via
Business Wire
Tickers
EWTX
Edgewise Therapeutics to Present at the Leerink Partners Global Biopharma Conference on March 11, 2024
March 05, 2024
From
Edgewise Therapeutics
Via
Business Wire
Tickers
EWTX
Edgewise Therapeutics to Present on EDG-5506 for the Treatment of Becker Muscular Dystrophy at the 2024 MDA Clinical and Scientific Conference
February 28, 2024
From
Edgewise Therapeutics
Via
Business Wire
Tickers
EWTX
Edgewise Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
February 22, 2024
From
Edgewise Therapeutics
Via
Business Wire
Tickers
EWTX
Edgewise Receives U.S. FDA Fast Track Designation for EDG-5506 for the Treatment of Duchenne Muscular Dystrophy (Duchenne)
February 13, 2024
From
Edgewise Therapeutics
Via
Business Wire
Tickers
EWTX
Edgewise Therapeutics Announces Pricing of $240 Million Underwritten Offering of Common Stock
January 19, 2024
From
Edgewise Therapeutics
Via
Business Wire
Tickers
EWTX
Edgewise Therapeutics Highlights 2023 Accomplishments and Anticipated Milestones for 2024 at the 42nd Annual J.P. Morgan Healthcare Conference
January 09, 2024
From
Edgewise Therapeutics
Via
Business Wire
Tickers
EWTX
Edgewise Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024
December 19, 2023
From
Edgewise Therapeutics
Via
Business Wire
Tickers
EWTX
Edgewise Therapeutics Launches First of Its Kind Educational Website Dedicated to the Becker Muscular Dystrophy Community
December 18, 2023
From
Edgewise Therapeutics
Via
Business Wire
Tickers
EWTX
Edgewise Receives Orphan Drug and Rare Pediatric Disease Designations for Its Muscular Dystrophy Program from FDA
November 30, 2023
From
Edgewise Therapeutics
Via
Business Wire
Tickers
EWTX
Edgewise Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights
November 09, 2023
From
Edgewise Therapeutics
Via
Business Wire
Tickers
EWTX
Edgewise Therapeutics to Present at Upcoming Investor Conferences
November 08, 2023
From
Edgewise Therapeutics
Via
Business Wire
Tickers
EWTX
Edgewise to Present Data on EDG-7500 at the American Heart Association’s Scientific Sessions 2023
November 01, 2023
From
Edgewise Therapeutics
Via
Business Wire
Tickers
EWTX
Edgewise Therapeutics Announces Expansion of their EDG-5506 Clinical Program in Duchenne Muscular Dystrophy (Duchenne)
October 26, 2023
From
Edgewise Therapeutics
Via
Business Wire
Tickers
EWTX
Edgewise Therapeutics to Present on EDG-5506 for Becker Muscular Dystrophy at the 28th International Annual Congress of the World Muscle Society
September 27, 2023
From
Edgewise Therapeutics
Via
Business Wire
Tickers
EWTX
< Previous
1
2
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.